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Abstract
Background: There is little evidence-based guidance on how to optimize methadone dosages among patients
with opioid addiction undergoing methadone maintenance treatment (MMT). This study aims to investigate whether
self-perceived opioid withdrawal symptoms, adverse effects, and self-reported substance use in patients on MMT are
related to serum methadone concentrations and the role that these variables could play in clinical decisions on dose
adjustments.
Methods: This naturalistic prospective cohort study included clinical and laboratory measurements from 83 patients
undergoing MMT in outpatient clinics in Bergen, Norway, from May 2017 to January 2020. Information on age, gender,
methadone daily doses and serum concentrations, subjective opioid withdrawal symptoms using 16 items Subjective
Opioid Withdrawal Scale (SOWS) questionnaire, self-reported adverse effects, and substance use was obtained. Linear
mixed modelling was used for analyzing the data.
Results: The mean age of the participants was 45 years, and 33% were women. Almost half reported mild to moderate
subjective opioid withdrawal symptoms, and all had experienced at least one subjective adverse effect. The use of at
least one substance was reported by 88% of the participants. Serum concentration-to-dose ratios were lower among
those who had reported subjective opioid withdrawal symptoms (p) = 0.039). The total SOWS score (p < 0.001); the
specific subjective withdrawal symptoms of anxiety (p = 0.004), bone and muscle aches (p = 0.003), restlessness (p =
0.017), and (slightly) shaking (p = 0.046), also use of heroin (p = 0.015) and alcohol (p = 0.011) were associated with
lower methadone concentrations. Cannabis use was slightly related to higher methadone concentrations (p = 0.049).
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Conclusions: The findings suggest that the patient’s self-perceived symptoms and current clinical condition are related
to the serum concentrations of methadone. This interpretation supports dose adjustments based on patient-reported
symptoms. In some aberrant cases, measurement of serum concentrations together with other individual assessments
may be considered to support the clinical decision.
Keywords: Methadone maintenance treatment, Serum concentrations, Subjective opioid withdrawal symptoms,
Adverse effects, Substance use, Opioid agonist treatment
Background
Methadone maintenance treatment (MMT) is an
evidence-based medical intervention that reduces illicit
opioid use and risk of overdose [1, 2] and mortality [3,
4] among opioid-dependent individuals. Understanding
factors that may influence treatment satisfaction and
continuity – and accordingly preventing a relapse to
illicit opioid use and the subsequent risk of overdose
and death – is crucial. Such factors may be opioid with-
drawal symptoms and adverse effects related to inappro-
priate methadone dosages. Thus, balancing an efficacious
dose to achieve the desired therapeutic effect against a
dose that is either too low, leading to withdrawal symp-
toms and relapse to illicit opioid use or too high, causing
adverse effects and toxicity, is important in clinical
practice.
Individualized dose optimization using daily doses of
between 60 and 120mg for most patients appears to be
related to increased retention in treatment and reduced
illicit opioid use as the most common measures of
MMT efficacy [5]. However interindividual variations in
methadone dose requirements should be kept in mind
[6–8]. Furthermore, some researchers have shown that
factors other than the dose – such as the patient’s ex-
pectations and medication preferences, as well as the pa-
tient’s total physical and mental health condition or
improvements in psychosocial functioning – may influ-
ence treatment satisfaction [9, 10]. These findings add to
the complexity of the issue challenging clinicians regard-
ing how to cope with suboptimal treatment outcomes:
should the dose be adjusted, or should other problems
instead be addressed?
One can predict the optimal methadone maintenance
dose using various factors based on continuous clinical
evaluations [11–13]. Although previous findings suggest
an association between the dose and clinical symptoms,
the relationships between serum methadone concentra-
tions and treatment effects are still not fully understood
[14]. Due to the large interindividual variation in metha-
done pharmacokinetics, individual serum concentrations
after a given dose will vary substantially [12, 14–16]. The
optimal dose at steady state thus is hard to predict [12].
Accordingly, a clinically oriented approach rather than
an approach based on serum levels has been suggested
for optimizing the methadone daily dosage for individual
patients [11, 12, 17].
Limited studies [18, 19], however, have suggested a
direct association between the serum methadone con-
centration and retention in treatment. A few clinical
studies [20, 21] have shown that when the serum con-
centration is too low to inhibit objective withdrawal
symptoms, patients relapse to substance use and drop
out of MMT. Other studies [11, 22, 23] have indicated
that higher concentrations are more likely to reduce opi-
oid craving. Finally, a rapid decline in the trough con-
centration is related to clinically important responses,
notably objective withdrawal symptoms [24]. However,
there is limited knowledge on the specific subjective
symptoms reflecting the serum concentrations of metha-
done, which clinicians must recognize to guide proper
dose adjustments in clinical practice.
The aim of this study is to investigate whether self-
perceived opioid withdrawal symptoms, adverse effects,
and substance use in patients on MMT are related to
serum methadone concentrations and the role that these
variables should play in clinical decisions on dose
adjustments.
Methods
Design, setting, and data sources
This naturalistic prospective cohort study was conducted
at the Department of Addiction Medicine at Haukeland
University Hospital in Bergen, Norway, from May 2017 to
January 2020. The department is responsible for the treat-
ment and follow-up of more than 1000 patients with opi-
oid dependence receiving opioid agonist treatment
(OAT). Almost 40% of these patients receive MMT, while
the rest mainly receive buprenorphine-based treatment.
All pharmacological interventions are integrated with psy-
chosocial treatment and are provided in multidisciplinary
outpatient clinics. The patients are followed-up via dir-
ectly observed treatment (DOT) and consultations, and
take-home doses frequencies are based on the individual
treatment courses. All clinical measurements and labora-
tory data are recorded prospectively in the hospital journal
system, as well as in a recently established health registry
database for patients undergoing OAT in Bergen. In
addition to incorporating individual health data, the
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database includes relevant information based on clinical
surveys and research records.
In the present study, we included information on age,
gender, daily methadone doses, serum methadone con-
centrations (as the independent variable), subjective opi-
oid withdrawal symptoms (as the primary outcome),
some common subjective opioid adverse effects and self-
reported illicit drug use (as the secondary outcomes).
We also included information about the time since last
dose intake, time of blood sampling, time when symp-
toms were recorded, numbers of days with DOT per
week, and duration of OAT.
Participants
One hundred and ninety-nine patients consented to par-
ticipate in the study and started the primary surveys
through in-person clinical interviews by a research
nurse. At the end of the study, 83 patients had com-
pleted the surveys according to the study protocol, with
the time difference between the clinical assessments and
laboratory measurements being < 14 days (Mean = 2,
SD = 3), and were included in the study.
Assessments of subjective symptoms
As part of the clinical assessments and based on the study
protocol, the participants were initially asked whether they
were experiencing opioid withdrawal symptoms. Those
who confirmed the presence of withdrawal symptoms
were interviewed by a research nurse using the validated
standard questionnaire, the Subjective Opioid Withdrawal
Scale (SOWS) [25], which covers 16 self-perceived symp-
toms: anxiety, yawning, perspiring, tearing, runny nose,
goosebumps, shaking, hot flushes, cold flushes, bone and
muscle aches, restlessness, nausea, vomiting, muscle
twitches, stomach cramps, and feeling like using. Respon-
dents rated the intensity of symptoms on a five-point scale
from 0 (not at all) to 4 (extreme); possible scores range
from 0 to 64 (1–10 =mild withdrawal, 11–20 =moderate
withdrawal, 21–30 = severe withdrawal).
In addition, all participants were asked six questions
on some of the most common subjective adverse effects
attributed to MMT, including euphoria, perspiring, nau-
sea, concentration difficulties, feeling “brain fog,” and re-
duced sexual desire; these symptoms were rated in the
same way as for the withdrawal symptoms. The selection
of the adverse effects was based on the authors clinical
experiences, previously published peer-collected data on
this population [10], and the most common reported
side effects for methadone [26, 27] and opioids in gen-
eral [28]. Perspiring and nausea were defined as adverse
effects or withdrawal symptoms based on how each par-
ticipant perceived them. In addition, one open-ended
question asked about other possible symptoms when
these were self-perceived to be related to MMT.
Substance use
Self-reported use of illicit drugs – including heroin or
other opioids, amphetamines (amphetamine and/or
methamphetamine), benzodiazepines, and cannabis – as
well as alcohol, and frequencies of use (categorized as no
use at all, or frequent use including either several times
a month, weekly, or daily use) during the last month
were recorded for the participants.
Measurements of serum methadone concentrations
Blood samples were drawn from the participants at the
OAT clinics according to the study protocol on average
21 (SD = 8) hours after the last dose intake, and no
changes in dosages were made during the week prior to
sampling. Analysis of methadone was performed by the
same analytical method using the same laboratory in-
struments at the Department of Medical Biochemistry
and Clinical Pharmacology, Haukeland University Hos-
pital, Bergen. During the development phase of the
method and in routine use, methadone concentrations
were measured in nmol/L. The conversion factor from
nmol/L to ng/mL for methadone is 0.310.
Statistical analyses
Basic descriptive statistical analysis of the data was per-
formed using Stata/SE 16.0 (StataCorp, TX, USA). Con-
tinuous variables were presented as means with standard
deviations (SD), as well as ranges when needed. Compar-
isons of study variables between the participants with
and without reported subjective opioid withdrawal
symptoms were performed using Mann–Whitney tests
for continuous variables and chi-square tests for categor-
ical variables. The exact p-values were reported, and
values < 0.05 were considered statistically significant. To
avoid type-II statistical errors by overlooking important
variables due to the study’s naturalistic design, we also
included variables with a p-value < 0.10 in the adjusted
regression analyses.
Linear mixed model (LMM) analysis was applied to in-
vestigate possible associations according to the aim of
the study. We included in the main analyses all 16
SOWS items, the 6 subjective adverse effects, and self-
reported substance use during the month prior to inter-
views as dependent variables. The responses to the
open-ended question were excluded from the statistical
analyses due to scant applicable data. All these variables
were included one by one in the unadjusted statistical
analyses. Then, adjusted LMM analyses for the specific
variables showing statistically significant associations
with the serum methadone concentration were under-
taken. The results obtained in the main analyses were
adjusted for age, gender, and the absolute time differ-
ence between blood sampling and the recording of the
symptoms.
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Results
Demographic and clinical data
Table 1 shows the demographic and clinical data of the
83 study participants and comparisons between those
with and without reported withdrawal symptoms as the
main outcome of the study. For all participants, the
mean age was 45 (SD = 9) years; 33% were women, and
54% reported mild to moderate subjective opioid with-
drawal symptoms with a mean total SOWS score of 9
(SD = 12) at the time of the interviews. The mean
methadone daily dose and serum concentration were 97
(SD = 24) mg and 374 (SD = 188) ng/mL, respectively.
Those who had reported subjective opioid withdrawal
symptoms had lower serum concentration-to-dose ratios
(p = 0.039), and more frequently received DOT (p =
0.026) compared to those in the other group. All had ex-
perienced one or more subjective adverse effects, and 73
(88%) reported frequent use of at least one substance
during the month prior to the surveys. There were no
differences between the groups with regard to age, gen-
der, or self-reported use of illicit substances and alcohol.
Relationships between subjective opioid withdrawal
symptoms and serum methadone concentrations
Figure 1 clarifies the relationship between the recorded
total SOWS scores and the measured serum methadone
concentrations, illustrating a weak correlation with wider
confidence intervals at lower and higher concentrations.
In the unadjusted LMM analysis (Table 2), we found sta-
tistically significant inverse associations, although weak to
moderate correlations, between serum methadone con-
centrations and total SOWS scores (p = 0.011), and for the
specific symptoms of anxiety (p = 0.009), bone and muscle
aches (p = 0.007), and restlessness (p = 0.021) out of the 16
subjective opioid withdrawal symptoms based on the
SOWS questionnaire, as well as for use of heroin (p =
0.028) and alcohol (p = 0.008). Except for a significant dir-
ect association with nausea reported as an adverse effect
of methadone (p = 0.040), no associations were found be-
tween the other subjective adverse medication effects and
methadone serum concentrations.
Adjustment of the results for confounding factors
When adjusting in the LMM analyses for age, gender,
and the absolute time difference between blood sampling
and the recording of the symptoms (Table 3), we found
that the associations between serum methadone concen-
trations and total SOWS scores; the specific withdrawal
symptoms of anxiety, bone and muscle aches, and rest-
lessness; and use of heroin and alcohol still remained
highly significant. There was a tendency toward higher
serum concentrations among those who reported nausea
as an adverse effect (p = 0.057). Obtaining p-values of <
0.10 by analyzing the withdrawal symptom of shaking as
well as use of cannabis in the unadjusted LMM, we also
added these variables to the adjusted model and found
Table 1 Demographic and clinical data in the study participants and comparisons between the groups with and without reported
subjective opioid withdrawal symptoms
All participants Withdrawals No withdrawals
N = 83 N = 45 N = 38 p-valuea
Gender, female/maleb 27/56 (33/67) 15/30 (56/54) 12/26 (44/46) 0.865
Age, yearsc 45 (9, 26–66) 45 (9, 26–62) 44 (10, 26–66) 0.493
Methadone dose, mg/dayc 97 (24, 20–170) 101 (24, 35–170) 92 (23, 20–150) 0.079
Methadone serum concentration, ng/mLc 374 (188, 74–1005) 347 (168, 113–1005) 405 (208, 74–998) 0.145
CDR,d (ng/mL)/(mg/day)c 4 (2, 1–11) 3 (2, 1–11) 4 (2, 1–9) 0.039
Time since last dose, hoursc 21 (8, 0–28) 22 (5, 1–28) 19 (10, 0–27) 0.199
Duration of opioid agonist treatmentc 9 (5, 1–20) 9 (5, 1–18) 9 (5, 1–20) 0.922
Direct observed treatment, day/weekc 4 (2, 1–7) 4 (2, 1–7) 3 (2, 1–6) 0.026
Self-reported substance use last monthb 73 (88) 41 (92) 32 (83) 0.187
Heroinb 10 (12) 5 (12) 5 (13) 0.971
Other opioidsb 5 (6) 3 (6) 2 (5) 0.819
Benzodiazepinesb 50 (62) 29 (64) 21 (55) 0.233
Cannabisb 55 (66) 30 (65) 25 (67) 0.828
Amphetamineb 26 (31) 15 (33) 11 (30) 0.789
Alcoholb 38 (46) 22 (49) 16 (42) 0.542
aSignificance was tested using Mann-Whitney U-test for continuous and chi-square test for categorical variables
bThe categorical variables are presented by n (%)
cThe continuous variables are presented as means with standard deviations (SD) and ranges
dConcentration-to-dose ratio
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slight associations with serum methadone concentra-
tions (p = 0.046 and p = 0.049, respectively).
Discussion
In clinical practice, there are different perceptions re-
garding what methadone dose adjustments should be
based on: subjective symptoms or serum concentration
measurements, and evidence on this topic is scarce. In
this naturalistic cohort study, we have shown associa-
tions between serum methadone concentrations and
subjective opioid withdrawal symptoms. Previous re-
search has reported an inverse relationship between
serum methadone concentrations and general objective
withdrawal symptoms [20, 21, 24], but to our knowledge,
no studies have investigated such relationships with sub-
jective withdrawal symptoms. Although the correlations
with the serum methadone concentration were not very
strong for these symptoms, the findings are in line with
existing theoretical expectations and support dose ad-
justments based on patient-reported symptoms in clin-
ical practice.
A lower serum concentration-to-dose ratio among more
than half the study participants who experienced with-
drawal symptoms is a remarkable finding, meaning that
serum concentrations were lower in this group despite
these participants’ having methadone doses comparable to
those of participants who did not report such symptoms.
This outcome may be partially explained by the fact that in-
creasing the dose was not met by a corresponding increase
in serum methadone concentration. Considering possible
aberrant methadone metabolisms or the influence of other
disturbing factors, individualized dose optimization based
on appropriate risk–benefit assessments might be empha-
sized as an approach capable of achieving treatment effects
[5–8, 12, 29]. Among those not experiencing the optimal
effect despite increasing the dose, dividing the daily dose or
converting to another opioid such as long-action morphine
can be considered [11, 24, 30]. When none of these mea-
sures can help, other causes such as pharmacodynamic fac-
tors and genetic variations affecting opioid receptors might
be excluded [6, 31]. Finally, diversion of prescribed metha-
done take-home doses may be considered as an explanation
for lower serum concentrations in the present study despite
patients’ receiving appropriate doses and frequently being
observed while taking their medications. Measurements of
serum concentrations can be considered in such aberrant
cases as a support to clinical decisions.
The higher use of heroin among those with lower
serum methadone concentrations is also in line with
earlier studies [20, 21, 23], indicating that even heroin
use may prompt physicians to consider dose escalation.
Using higher methadone doses is more effective in redu-
cing heroin use and improving treatment retention [32–
34]. However, some patients continue using heroin for
its euphoric effects or other reasons, regardless of their
serum methadone concentration. In addition, it is not
clear whether the lower serum concentration causes the
heroin use or whether some patients intentionally do
not use the full dose prescribed to allow the heroin to be
felt. It is challenging to answer these questions consider-
ing the naturalistic design of the study. Our finding of
higher alcohol use among those with lower serum
methadone concentrations could be explained by self-
experienced replacement to alleviate opioid withdrawal
Fig. 1 Scatter plot with regression line by recorded total SOWSa scores and measured serum methadone concentrations in 83 participants. The
solid and dashed lines represent the regression line and 95% confidence intervals. a Subjective opioid withdrawal symptoms
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symptoms. Research has also demonstrated an overlap-
ping effect of alcohol on mu-opioid receptors in the cen-
tral nervous system [35]. In addition, regular low-dose
alcohol intake (< 4 alcoholic drink/day) may induce P450
enzymes and thus decrease serum methadone concen-
trations [26]. Considering the increased risk of adverse
effects and overdose with the concurrent use of opioids
and alcohol, a balanced dosage strategy is important to
increase treatment retention and avoid not only relapse
but also toxicity.
Although all participants reported at least one subject-
ive adverse effect related to methadone treatment, none
of these symptoms were significantly related to serum
concentrations, except for a slight association with nau-
sea. Studies on such associations are lacking. Neverthe-
less, it is important to keep in mind other possible
physical and psychosocial conditions surrounding the
patient, which may influence the total subjective experi-
ence and satisfaction with the treatment [10]. The inabil-
ity to identify some associations in the present study
may also be due to the group-level investigation. Follow-
ing individuals over time with different doses may have
revealed some associations. Additionally, we used self-
reported responses to a locally developed questionnaire
on common subjective adverse effects, not a validated
instrument, which could have more accurately captured
possible adverse effects.
The participants with higher serum methadone con-
centrations seemed to use more cannabis. Although the
slight association may be due to a type-I error, the find-
ing is of theoretical and clinical interest. A possible
mechanism may be a central-acting effect to counterbal-
ance undesirable side effects related to methadone treat-
ment, for instance, an antiemetic effect of cannabis [36].
Some researchers have also suggested an opioid-saving
effect of cannabis in patients with opioid dependence
[37]. However, use of cannabis was not associated with
MMT retention in a review article [38] and could not
predict treatment outcomes such as relapse to heroin
use or psychosocial functioning. To our knowledge, clin-
ical studies have not yet examined possible associations
Table 2 The unadjusted associations between serum
methadone concentrations and the study variables in 83
participants. All the primary and secondary outcome variables
were inserted one by one in linear mixed model
β-coefficient 95% CIa p-value
Total SOWSb score − 3.9 − 7, − 9.1 0.011
Anxiety − 4.3 − 7.6, − 1.1 0.009
Yawning − 0.5 − 3.5, 2.5 0.739
Perspiring − 0.4 − 4.1, 3.3 0.821
Tearing − 1.5 − 4.1, 1.2 0.283
Nose run − 1.7 − 4.9, 1.5 0.305
Goose bumps − 2.1 − 5.5, 1.4 0.244
Shaking − 2.7 − 5.7, 0.3 0.081
Hot flushes − 2.6 − 6.2, 8.9 0.143
Cold flushes − 3.2 − 7.1, 0.8 0.115
Bone- and muscle ache − 4.9 − 8.4, − 1.4 0.007
Restlessness − 5.2 − 9.6, − 0.8 0.021
Nausea − 1.5 − 4.2, 1.2 0.272
Vomitingd – – –
Muscle twitches − 0.9 − 4.2, 2.4 0.590
Stomach cramps − 1.5 − 4.2, 1.1 0.263
Feel like usingd – – –
Subjective adverse effectsd – – –
Euphoriad – – –
Perspiring (as adverse effect) 1.4 − 3.0, 5.9 0.526
Nausea (as adverse effect) 3.1 0.1, 6.1 0.040
Concentration difficulties − 0.7 − 4.7, 3.3 0.731
Feeling “brain fog” 1.5 − 2.2, 5.2 0.427
Decreased sexual desire 2.2 − 2.4, 6.8 0.351
Self-reported substance use c 0.2 − 0.9, 1.3 0.754
Heroin − 2 − 3.8, − 0.2 0.028
Other opioidsd – – –
Benzodiazepines 0.6 − 3.7, 4.9 0.772
Cannabis 4.7 − 0.5, 9.9 0.077
Amphetamines − 0 − 3.0, 2.9 0.984
Alcohol − 4.5 − 7.8, − 1.2 0.008
a Confidence interval
b Subjective opioid withdrawal symptoms
c Frequent use (from daily to several times a month) of illicit drugs and alcohol
during the month prior to surveys
d The linear mixed model system was not able to analyze these variables due
to scant data
Table 3 Associations between serum methadone
concentrations and the study variables in 83 participants by
using adjusteda linear mixed model
β-coefficient 95% CI b p-value
Total SOWSc Score − 4.3 − 5.6, − 2.9 < 0.001
Anxiety − 0.5 − 0.8, − 0.2 0.004
Bone- and muscle ache − 0.5 − 0.9, − 0.2 0.003
Restlessness − 0.5 − 9.7, − 0.9 0.017
Shaking − 0.3 − 0.6, − 0 0.046
Nausea (as adverse effect) 0.3 − 0.1, 0.6 0.057
Heroin use − 0.2 − 0.4, − 0 0.015
Alcohol use − 0.4 − 0.7, − 0.1 0.011
Cannabis use 0.5 0, 10.4 0.049
a Adjusted for age, gender and absolute time difference between blood
sampling and record of the symptoms
b Confidence interval
c Subjective opioid withdrawal symptoms
Chalabianloo et al. Substance Abuse Treatment, Prevention, and Policy           (2021) 16:39 Page 6 of 8




The prospective nature of our study and the treatment
platform allowed us to continuously meet the patients or
repeat records if needed. We were thus able to manage
the data collection more closely and reduce information
bias. This design might be considered as a strength of
the study.
Limitations
We were not able to perform all the interviews and
blood tests at the same time (delayed follow-up), as
some patients did not attend the planned interviews or
could not complete the measurements at the same time.
As a result, approximately half of those who had com-
pleted the primary surveys were eligible to be included
in the study. Furthermore, although the study found as-
sociations between some subjective symptoms and
serum methadone concentrations, the results must be
interpreted in light of the relatively small effect sizes.
The observed weak to moderate correlations may reflect
possible influences of other factors such as concurrent
use of illicit drugs or abstinence from these substances,
comorbid somatic and psychiatric conditions, or even
manipulation of symptoms to receive higher methadone
doses. Another limitation may be the small sample size
and possibility for some uncovered associations. Further
clinical studies are needed to obtain more knowledge in
this field.
Conclusions
Subjective opioid withdrawal symptoms – particularly
anxiety, bodily pain, restlessness, and shaking (slightly) –
and self-reported use of heroin and alcohol were associ-
ated with lower serum methadone concentrations. Pa-
tients with higher serum methadone concentrations had
a tendency to use more cannabis. As the concentration
of methadone in serum was related to the patient’s self-
reported symptoms and use of substances, such symp-
toms may support the need for dose adjustments. Divid-
ing the dose or converting to other opioids should be
considered when dose escalations do not relieve the
symptoms. Measurements of serum concentrations can
be considered in some aberrant cases as a support to
clinical decisions.
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